Efficiency of noopept in streptozotocin-induced diabetes in rats

Bull Exp Biol Med. 2013 Jan;154(3):334-8. doi: 10.1007/s10517-013-1944-4.


We studied the effects of new nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) in various dosage regimens on the dynamics of glycemia, body weight, and pain sensitivity in rats receiving diabetogenic toxin streptozotocin. In experimental diabetic rats, Noopept alleviated glycemia and weight loss and normalized enhanced pain sensitivity. The normalizing effect of Noopept was most pronounced when it was administered as a preventive agent prior to injection of the toxin. Both preventive and therapeutic administration of Noopept (delayed injections included) significantly weakened the examined metabolic effects of diabetogenic toxin. Possible mechanisms of the antidiabetic action of Noopept are analyzed.

MeSH terms

  • Animals
  • Antioxidants / metabolism
  • Body Weight / drug effects
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / prevention & control*
  • Dipeptides / therapeutic use*
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Neuroprotective Agents / therapeutic use*
  • Nootropic Agents / therapeutic use*
  • Pain / drug therapy
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Streptozocin


  • Antioxidants
  • Dipeptides
  • Hypoglycemic Agents
  • Neuroprotective Agents
  • Nootropic Agents
  • ethyl phenylacetyl-Pro-Gly
  • Streptozocin